多索茶碱与布地奈德雾化治疗急性支气管哮喘患者的效果分析
|
摘要
目的研究多索茶碱与布地奈德雾化对急性支气管哮喘患者的疗效及一秒用力呼气容积(FEV1)、用力肺活量(FVC)、呼气峰流速值(PET)水平的影响。方法选取从2016年1月至2018年1月我院收治的急性支气管哮喘患者100例进行研究,将其以随机抽签法均分成试验组和对照组。对照组予以布地奈德雾化治疗,试验组则在布地奈德雾化治疗的基础上增用多索茶碱治疗。分别比较两组在临床疗效,治疗前后FEV1、FVC、PEF水平,治疗前后血清白细胞介素-4(IL-4)、γ干扰素(IFN-γ)水平以及不良反应发生情况等方面的差异。结果试验组与对照组在总有效率方面对比,试验组高于对照组(P<0.05)。治疗后试验组与对照组在FEV1、FVC、PEF水平方面对比,试验组高于对照组(P<0.05)。治疗后试验组与对照组在血清IL-4、IFN-γ水平方面比较,试验组IL-4水平低于对照组,而IFN-γ水平高于对照组(均P<0.05)。试验组与对照组在不良反应发生率方面对比,试验组低于对照组(P<0.05)。结论多索茶碱与布地奈德雾化联合应用于急性支气管哮喘患者中的疗效显著,有利于改善患者肺功能以及免疫功能,且可显著降低不良反应发生风险。
Objective To study the efficacy of doxofylline and budesonide atomization on patients with acute bronchial asthma, and to analyze the effects of one-second forced expiratory volume(FEV1), forced pulmonary capacity(FVC) and expiratory peak velocity(PET) levels. Methods A total of 100 patients with acute bronchial asthma admitted to our hospital from January 2016 to January 2018 were selected for study, and they were divided into experimental group and control group by random lottery. The control group was atomized with budesonide, while the experimental group was treated with doxofylline on the basis of budesonide atomization. Clinical efficacy, levels of FEV1, FVC, PEF, serum interleukin-4(IL-4), gamma interferon(IFN-γ) and adverse reactions before and after treatment were compared between the two groups. Results The total effective rate of the experimental group was higher than that of the control group(P <0.05).After treatment, the levels of FEV1, FVC and PEF in the experimental group and the control group were higher than those in the control group(all P<0.05).After treatment, the levels of serum IL-4 and ifn-gamma in the experimental group and the control group were lower than those in the control group, while the levels of IFN-γ were higher than those in the control group(all P<0.05).The incidence of adverse reactions between the experimental group and the control group was lower than that of the control group(P<0.05). Conclusion Doxofylline combined with budesonide atomization has a significant therapeutic effect in patients with acute bronchial asthma, which is conducive to improving the pulmonary function and immune function of patients and significantly reducing the risk of adverse reactions.
Objective To study the efficacy of doxofylline and budesonide atomization on patients with acute bronchial asthma, and to analyze the effects of one-second forced expiratory volume(FEV1), forced pulmonary capacity(FVC) and expiratory peak velocity(PET) levels. Methods A total of 100 patients with acute bronchial asthma admitted to our hospital from January 2016 to January 2018 were selected for study, and they were divided into experimental group and control group by random lottery. The control group was atomized with budesonide, while the experimental group was treated with doxofylline on the basis of budesonide atomization. Clinical efficacy, levels of FEV1, FVC, PEF, serum interleukin-4(IL-4), gamma interferon(IFN-γ) and adverse reactions before and after treatment were compared between the two groups. Results The total effective rate of the experimental group was higher than that of the control group(P <0.05).After treatment, the levels of FEV1, FVC and PEF in the experimental group and the control group were higher than those in the control group(all P<0.05).After treatment, the levels of serum IL-4 and ifn-gamma in the experimental group and the control group were lower than those in the control group, while the levels of IFN-γ were higher than those in the control group(all P<0.05).The incidence of adverse reactions between the experimental group and the control group was lower than that of the control group(P<0.05). Conclusion Doxofylline combined with budesonide atomization has a significant therapeutic effect in patients with acute bronchial asthma, which is conducive to improving the pulmonary function and immune function of patients and significantly reducing the risk of adverse reactions.
引文
[1]Kim MH,Kim SH,Park SY,et al.Characteristics of Adult Severe Refractory Asthma in Korea Analyzed From the Severe Asthma Registry[J].Allergy Asthma Immunol Res,2019,11(1):43-54.
[2]张荣,陈亮.多索茶碱与氨茶碱在支气管哮喘患者中的疗效对比观察及对肺功能的影响研究[J].湖南师范大学学报(医学版),2017,14(4):167-169.
[3]孙怡,赵长伟,肖辉,等.多索茶碱联合布地奈德治疗支气管哮喘急性发作的疗效及对炎症因子的影响[J].世界临床医学,2017,11(18):88-89.
[4]徐如平,吴自平,徐静,等.射干麻黄汤加减联合多索茶碱治疗支气管哮喘的临床研究[J].中国生化药物杂志,2017,37(10):64-65.
[5]惠慧.多索茶碱联合布地奈德雾化吸入治疗支气管哮喘急性发作的疗效分析[J].实用妇科内分泌电子杂志,2017,4(32):14-15.
[6]李吉梅,孙成英,娄明远,等.多索茶碱注射液对急性支气管哮喘患者血清IL-18,IL-33及TNF-α水平的影响[J].现代生物医学进展,2017,17(21):4116-4119.
[7]Panicker V,Sulaiman SP.Serum Ig E Level among Coir Workers with Asthma:A Hospital Based Descriptive Study from Alappuzha,Kerala[J].J Assoc Physicians India,2018,66(5):45-47.
[8]胡业焕,谭海涛,曾佩敏,等.氨茶碱与多索茶碱在支气管哮喘治疗中的临床有效性对比分析[J].现代诊断与治疗,2016,27(6):1043-1044.
[9]张静玉,王彦辉,张明亮,等.多索茶碱与盐酸氨溴索联合治疗支气管哮喘急性期患者的临床疗效观察[J].西北药学杂志,2016,33(2):192-194.
[10]陈郴,王琦,孟广平,等.支气管哮喘急性发作患者应用多索茶碱与可必特治疗对其不良反应的影响[J].临床医药文献电子杂志,2016,3(33):6646-6648.
[11]范菱.多索茶碱联合吸入剂治疗支气管哮喘急性发作的临床研究[J].海南医学院学报,2018,24(5):581-584.
[12]俞彦荣,仇小云.布地奈德联合多索茶碱治疗支气管哮喘急性发作的临床观察[J].中西医结合心血管病电子杂志,2017,5(9):17-18.
[13]谢俊大,毛敏,黄凤,等.多索茶碱与氨茶碱改善支气管哮喘患者肺通气指标的临床观察Meta分析[J].中国现代医生,2018,56(5):25-29.
[14]逯萍,秦英季,卢旭,等.多索茶碱片联合沙丁胺醇治疗急性支气管哮喘的效果分析[J].中国临床实用医学,2018,9(4):63-64.
[15]刘勇进,张意仲,俞列群,等.多索茶碱联合糖皮质激素治疗对老年支气管哮喘急性发作患者肺功能和细胞因子的影响[J].浙江临床医学,2018,20(3):445-447.
[16]李娟.多索茶碱联合雾化吸入可必特治疗支气管哮喘急性发作的疗效及对肺功能的影响[J].临床医学研究与实践,2018,3(30):21-22.
[17]徐友文,李婉红,张亚琼,等.布地奈德对支气管哮喘儿童血CKLF-1、IL-4和IFN-γ水平的影响[J].中华全科医学,2015,13(6):992-995.
[18]曹雯,杜永成,李毅,等.烟雾暴露对支气管哮喘大鼠CCR7和Th1/Th2细胞因子表达的影响[J].中华医学杂志,2018,98(28):2264-2268.
[19]焦文妤,张福康.多索茶碱和氨茶碱静脉滴注与糖皮质激素类药物治疗支气管哮喘急性发作临床效果及安全性对比研究[J].陕西医学杂志,2018,47(9):1185-1188.
[20]Kang Q,Zhang X,Liu S,et al.Correlation between the vitamin D levels and asthma attacks in children:Evaluation of the effects of combination therapy of atomization inhalation of budesonide,albuterol and vitamin D supple mentation on asthmatic patients[J].Exp Ther Med,2018,15(1):727-732.
[2]张荣,陈亮.多索茶碱与氨茶碱在支气管哮喘患者中的疗效对比观察及对肺功能的影响研究[J].湖南师范大学学报(医学版),2017,14(4):167-169.
[3]孙怡,赵长伟,肖辉,等.多索茶碱联合布地奈德治疗支气管哮喘急性发作的疗效及对炎症因子的影响[J].世界临床医学,2017,11(18):88-89.
[4]徐如平,吴自平,徐静,等.射干麻黄汤加减联合多索茶碱治疗支气管哮喘的临床研究[J].中国生化药物杂志,2017,37(10):64-65.
[5]惠慧.多索茶碱联合布地奈德雾化吸入治疗支气管哮喘急性发作的疗效分析[J].实用妇科内分泌电子杂志,2017,4(32):14-15.
[6]李吉梅,孙成英,娄明远,等.多索茶碱注射液对急性支气管哮喘患者血清IL-18,IL-33及TNF-α水平的影响[J].现代生物医学进展,2017,17(21):4116-4119.
[7]Panicker V,Sulaiman SP.Serum Ig E Level among Coir Workers with Asthma:A Hospital Based Descriptive Study from Alappuzha,Kerala[J].J Assoc Physicians India,2018,66(5):45-47.
[8]胡业焕,谭海涛,曾佩敏,等.氨茶碱与多索茶碱在支气管哮喘治疗中的临床有效性对比分析[J].现代诊断与治疗,2016,27(6):1043-1044.
[9]张静玉,王彦辉,张明亮,等.多索茶碱与盐酸氨溴索联合治疗支气管哮喘急性期患者的临床疗效观察[J].西北药学杂志,2016,33(2):192-194.
[10]陈郴,王琦,孟广平,等.支气管哮喘急性发作患者应用多索茶碱与可必特治疗对其不良反应的影响[J].临床医药文献电子杂志,2016,3(33):6646-6648.
[11]范菱.多索茶碱联合吸入剂治疗支气管哮喘急性发作的临床研究[J].海南医学院学报,2018,24(5):581-584.
[12]俞彦荣,仇小云.布地奈德联合多索茶碱治疗支气管哮喘急性发作的临床观察[J].中西医结合心血管病电子杂志,2017,5(9):17-18.
[13]谢俊大,毛敏,黄凤,等.多索茶碱与氨茶碱改善支气管哮喘患者肺通气指标的临床观察Meta分析[J].中国现代医生,2018,56(5):25-29.
[14]逯萍,秦英季,卢旭,等.多索茶碱片联合沙丁胺醇治疗急性支气管哮喘的效果分析[J].中国临床实用医学,2018,9(4):63-64.
[15]刘勇进,张意仲,俞列群,等.多索茶碱联合糖皮质激素治疗对老年支气管哮喘急性发作患者肺功能和细胞因子的影响[J].浙江临床医学,2018,20(3):445-447.
[16]李娟.多索茶碱联合雾化吸入可必特治疗支气管哮喘急性发作的疗效及对肺功能的影响[J].临床医学研究与实践,2018,3(30):21-22.
[17]徐友文,李婉红,张亚琼,等.布地奈德对支气管哮喘儿童血CKLF-1、IL-4和IFN-γ水平的影响[J].中华全科医学,2015,13(6):992-995.
[18]曹雯,杜永成,李毅,等.烟雾暴露对支气管哮喘大鼠CCR7和Th1/Th2细胞因子表达的影响[J].中华医学杂志,2018,98(28):2264-2268.
[19]焦文妤,张福康.多索茶碱和氨茶碱静脉滴注与糖皮质激素类药物治疗支气管哮喘急性发作临床效果及安全性对比研究[J].陕西医学杂志,2018,47(9):1185-1188.
[20]Kang Q,Zhang X,Liu S,et al.Correlation between the vitamin D levels and asthma attacks in children:Evaluation of the effects of combination therapy of atomization inhalation of budesonide,albuterol and vitamin D supple mentation on asthmatic patients[J].Exp Ther Med,2018,15(1):727-732.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |